8-K: IQVIA Q3 2025 Results: Revenue Up, Free Cash Flow Soars

IQVIA Holdings Inc. announced robust third-quarter 2025 financial results, with revenue up 5.2% and free cash flow increasing 35% year-over-year, while reaffirming its full-year guidance.

Summary

• Third-quarter 2025 revenue reached $4,100 million, marking a 5.2% increase on a reported basis and 3.9% at constant currency compared to Q3 2024.
• GAAP Net Income for the quarter was $331 million, with GAAP Diluted Earnings per Share at $1.93.
• Adjusted EBITDA for Q3 2025 was $949 million, a 1.1% increase year-over-year, and Adjusted Diluted Earnings per Share was $3.00.
• Research & Development Solutions (R&DS) recorded quarterly bookings of $2.6 billion, achieving a book-to-bill ratio of 1.15x.
• The R&DS contracted backlog stood at $32.4 billion as of September 30, 2025, representing a 4.1% year-over-year increase.
• Operating Cash Flow for the third quarter was $908 million, and Free Cash Flow was $772 million, up 35% year-over-year and representing 150% of Adjusted Net Income.
• Full-year 2025 guidance was reaffirmed at the midpoint and narrowed, with expected revenue between $16,150 million and $16,250 million, Adjusted EBITDA between $3,775 million and $3,800 million, and Adjusted Diluted Earnings per Share between $11.85 and $11.95.

Sentiment

Score: 8

Explanation: The company reported strong Q3 results with revenue and profit at the high end of guidance, record free cash flow, and robust R&D bookings. The reaffirmation and narrowing of full-year guidance indicate confidence. However, Adjusted EBITDA growth was modest, and year-to-date GAAP net income and EPS saw a slight decline compared to the previous year.

Positives

• Revenue increased 5.2% on a reported basis and 3.9% at constant currency to $4,100 million in Q3 2025, reaching the high-end of guidance.
• Free Cash Flow surged 35% year-over-year to $772 million, representing a record generation and 150% of Adjusted Net Income.
• R&D Solutions bookings were strong at $2.6 billion, with a healthy book-to-bill ratio of 1.15x, indicating future revenue growth.
• R&D Solutions contracted backlog grew 4.1% year-over-year to $32.4 billion, providing revenue visibility.
• Management noted strong demand across all customer segments and improved client decision timelines for R&DS, leading to 13% growth in net bookings year-over-year.
• RFP growth accelerated to 20% year-over-year, signaling robust demand indicators.
• Full-year 2025 guidance midpoint was reaffirmed, with narrowed ranges, suggesting confidence in future performance.

Negatives

• Adjusted EBITDA growth was modest at 1.1% year-over-year, reaching $949 million.
• Technology & Analytics Solutions (TAS) revenue growth of 5.0% reported (3.3% constant currency) was achieved despite a tougher year-over-year comparison.
• Net income attributable to IQVIA Holdings Inc. for the nine months ended September 30, 2025, was $846 million, a decrease from $936 million in the same period of 2024.
• GAAP Diluted Earnings per Share for the nine months ended September 30, 2025, was $4.86, down from $5.08 in the same period of 2024.

Risks

• Business disruptions caused by natural disasters, pandemics (such as COVID-19 variants), international conflicts, or other disruptions outside of control.
• Most contracts may be terminated on short notice, potentially leading to loss or delays with large client contracts or inability to enter new ones.
• The market for services may not grow as expected.
• Inability to successfully develop and market new services or enter new markets.
• Imposition of restrictions on data use by data suppliers or their refusal to license data.
• Failure to comply with contractual, regulatory, or ethical requirements, including current or future changes to data protection and privacy laws.
• Breaches or misuse of security or communications systems, or those of outsourcing partners.
• Failure to meet productivity or business transformation objectives.
• Failure to successfully invest in growth opportunities.
• Ability to protect intellectual property rights and susceptibility to claims of infringement by others.
• Expiration or inability to acquire third-party licenses for technology or intellectual property.
• Failure to accurately and timely price and formulate cost estimates for contracts, or to document change orders.
• Hardware and software failures, delays in system operation, or failure to implement system enhancements.
• The rate at which backlog converts to revenue.
• Ability to acquire, develop, and implement technology necessary for the business.
• Consolidation in the industries in which clients operate.
• Risks related to client or therapeutic concentration.
• Government regulators limiting the number or scope of indications for medicines and treatments, withdrawing products, or imposing new regulatory requirements.
• Risks associated with operating on a global basis, including currency or exchange rate fluctuations and legal compliance, such as anti-corruption laws.
• Risks related to the enactment of legislation or the imposition of regulations or other restrictions or actions by governments that create business uncertainty and have the potential to limit trade.
• Risks related to changes in accounting standards.
• General economic conditions in the markets of operation, including financial market conditions, inflation, and risks related to sales to government entities.
• The impact of changes in tax laws and regulations.
• Ability to successfully integrate acquired businesses and achieve expected benefits.

Future Outlook

The company reaffirmed the midpoint of its full-year 2025 guidance and narrowed the ranges for revenue ($16,150 million to $16,250 million), Adjusted EBITDA ($3,775 million to $3,800 million), and Adjusted Diluted Earnings per Share ($11.85 to $11.95). This guidance includes an estimated $100 million COVID-related revenue step-down, entirely in R&DS, approximately 100 basis points of tailwind from foreign exchange, and approximately 150 basis points of contribution from acquisitions. Management expressed confidence in sustaining top and bottom-line growth performance due to continued execution and healthy demand indicators.

Management Comments

• "IQVIA delivered a strong quarter with revenue and profit towards the high-end of our guide, and record free cash flow generation." Ari Bousbib, chairman and CEO.
• "R&DS continued to perform well, with strong demand across all customer segments and improved client decision timelines leading to 13 percent growth in net bookings year-over-year." Ari Bousbib, chairman and CEO.
• "TAS delivered solid results despite a tougher year-over-year comparison, driven by ongoing momentum from drug launches and the strength of our broader commercial portfolio." Ari Bousbib, chairman and CEO.
• "With continued execution across the business and healthy demand indicators, such as RFP growth accelerating to 20 percent year-over-year, we remain confident in our ability to sustain our top and bottom-line growth performance." Ari Bousbib, chairman and CEO.

Industry Context

IQVIA operates as a leading global provider of clinical research services, commercial insights, and healthcare intelligence. The strong R&DS bookings and backlog, coupled with accelerating RFP growth, suggest a healthy demand environment within the life sciences and healthcare industries for outsourced research and development services. The mention of "ongoing momentum from drug launches" for TAS indicates a positive trend in pharmaceutical innovation and commercialization. The company's focus on "IQVIA Connected Intelligence," "Healthcare-grade AI," and "advanced analytics" positions it at the forefront of technology adoption in the healthcare sector, aligning with broader industry trends towards digital transformation and data-driven decision-making.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, record free cash flow, reaffirmed guidance, and robust R&D bookings, potentially leading to increased shareholder value.
• Customers (Life Sciences & Healthcare Industries): Continued strong demand for IQVIA's clinical research services, commercial insights, and healthcare intelligence, indicating ongoing reliance on their solutions for drug development and commercialization.
• Employees: Continued execution and growth across the business suggest stability and potential opportunities within the company, which has approximately 91,000 employees globally.

Next Steps

• Host a conference call at 9:00 a.m. Eastern Time on October 28, 2025, to discuss Q3 2025 results and Q4/full-year 2025 guidance.
• Continue execution across the business to sustain top and bottom-line growth performance.

Key Dates

Recommendation

The company delivered strong third-quarter results, exceeding expectations on revenue and profit, and achieving record free cash flow. The robust R&D Solutions bookings and backlog, coupled with accelerating RFP growth, indicate strong underlying demand and future revenue visibility. Reaffirming and narrowing the full-year guidance demonstrates management's confidence. While Adjusted EBITDA growth was modest and year-to-date GAAP net income declined slightly, the overall operational strength, cash generation, and positive outlook make it an attractive investment.

Keywords

IQVIA, clinical research, healthcare intelligence, life sciences, pharmaceutical, biotech, CRO, contract research organization, financial results, Q3 2025, earnings, revenue, EBITDA, free cash flow, backlog, R&D Solutions, Technology & Analytics Solutions, Contract Sales & Medical Solutions, SEC filing